Introduction {#Sec1}
============

Asthma disproportionately affects racial and ethnic populations. In the US in 2006, the age-adjusted, asthma-related mortality rates were approximately 3 times higher in non-Hispanic Blacks than in non-Hispanic Whites and Hispanics.\[[@CR1]\] Although typical safety and efficacy studies are underpowered or too short in duration to make definitive conclusions regarding severe asthma exacerbations (i.e. those requiring systemic corticosteroids), important insight into the efficacy of medications can be gained from analyzing related moderate exacerbation events characterized by a sustained loss of asthma control (beyond normal day-to-day variation) that does not meet the definition of a severe exacerbation.\[[@CR2]\] For the purpose of asthma research protocol development, moderate exacerbation events have been captured using various terminology, such as asthma deterioration,\[[@CR3]\] asthma worsenings,\[[@CR4]\] and asthma events.\[[@CR5]\] Few US studies have evaluated the safety and efficacy of an inhaled corticosteroid (ICS)/long-acting β~2~-adrenergic agonist (LABA) combination therapy in Black or Hispanic patients with asthma. The efficacy of budesonide/formoterol (BUD/FM) pressurized metered-dose inhaler (pMDI) has been evaluated in randomized, double-blind studies in predominantly White patients with mild to moderate asthma\[[@CR6]\] and predominantly White,\[[@CR5]\] Black,\[[@CR7]\] and Hispanic\[[@CR8]\] patients with moderate to severe asthma. Results for a predefined asthma event definition, which encompass moderate to severe asthma deteriorations, are presented as these findings have not been presented previously in detail or compared across patient populations.

Methods {#Sec2}
=======

[Table I](#Tab1){ref-type="fig"} includes a brief summary of the studies that were included in this exploratory analysis. Additional details of the individual studies, including study design and methods, have been previously described.\[[@CR5]--[@CR8]\] This analysis of predefined asthma events ([table II](#Tab2){ref-type="fig"}) includes data from patients aged ≥12 years with asthma who were enrolled in randomized, double-blind, 12-week US studies that differed according to baseline asthma severity and/or race or ethnicity ([table III](#Tab3){ref-type="fig"}). Only the BUD/FM and BUD treatment arms, which were common to all four studies, are presented; these studies were not originally powered for comparison of asthma events.

![Study treatments and entry criteria\[[@CR5]--[@CR8]\]](40268_2012_12010009_Tab1){#Tab1}

![Predefined criteria for asthma events\[[@CR5]--[@CR8]\]](40268_2012_12010009_Tab2){#Tab2}

![Patient demographic and baseline clinical characteristics\[[@CR5]--[@CR8]\] ^a,b^](40268_2012_12010009_Tab3){#Tab3}

Statistical methods for this analysis are similar to those described previously.\[[@CR5]--[@CR8]\] Comparisons among treatment groups of percentages of patients who experienced ≥1 predefined asthma event and of percentages of patients who withdrew because of such an event were performed by χ^2^ test (study I) or Cochran-Mantel-Haenszel test with adjustment for treatment (studies III and IV) and ICS dose (medium or high; studies II, III, and IV) at study entry.

Results {#Sec3}
=======

Baseline demographics were similar across studies ([table II](#Tab2){ref-type="fig"}). As expected, patients with mild to moderate asthma had better pulmonary function than those with moderate to severe asthma.

The percentage of patients with moderate to severe asthma who experienced ≥1 asthma event was lower in the BUD/FM groups versus the BUD group, with statistically significant differences observed in study II (p \< 0.05) \[[figure 1](#Fig1){ref-type="fig"}\]. In all studies, the most commonly met predefined criterion was night-time awakening. The predefined criterion of clinical exacerbation included the following subcategories that were not mutually exclusive: study I (BUD/FM: one patient \[one emergency department (ED) visit, one event of disallowed asthma medication use\], BUD: three patients \[one ED visit, three events of disallowed asthma medication use\]);study II (BUD/FM: seven patients \[three ED visits, seven events of disallowed asthma medication use\], BUD: five patients \[one ED visit, four events of disallowed asthma medication use\]);study III (BUD/FM: three patients \[two events of disallowed asthma medication use, one event of nebulized bronchodilator use, three events of oral corticosteroid use\], BUD: three patients \[one ED visit, three events of disallowed asthma medication use, one event of nebulized bronchodilator use, and three events of oral corticosteroid use\]);study IV (BUD/FM: seven patients \[two ED visits, two hospitalizations --- one due to multiple significant/active comorbidities and one due to viral infection, seven events of disallowed asthma medication use\], BUD: two patients \[two events of disallowed medication use\]).

![Percentages of patients with ≥1 predefined asthma event (overall and individual events) and withdrawals due to predefined asthma event in (**a**) study I (predominantly White patients with mild to moderate asthma), (**b**) study II (predominantly White patients with moderate to severe asthma), (**c**) study III (Black patients), and (**d**) study IV (Hispanic patients). **bid** = twice daily; **BUD** = budesonide; **DPI** = dry powder inhaler; **FEV** ~1~ = forced expiratory volume in 1 second; **FM** = formoterol; **PEF** = peak expiratory flow; **pMDI** = pressurized metered-dose inhaler; \* p \< 0.05 vs BUD.](40268_2012_12010009_Fig1){#Fig1}

Overall, withdrawal rates were lower in studies I and IV than in studies II and III ([figure 1](#Fig1){ref-type="fig"}). The percentage of patients with mild to moderate asthma (study I) who withdrew due to ≥1 predefined asthma event was similar in the BUD/FM and BUD groups. Percentages of patients with moderate to severe asthma (studies II, III, and IV) who withdrew due to ≥1 asthma event were numerically lower in the BUD/FM versus BUD groups, regardless of race. Additional results from the individual studies have been previously described.\[[@CR5]--[@CR8]\]

Conclusions {#Sec4}
===========

Predefined asthma events are increasingly being utilized in clinical research studies as a sensitive composite control metric. An asthma event metric encompassing measures of pulmonary function, symptoms, rescue medication use, and the need for additional medications was investigated in the present analysis. While individual studies were not powered for statistical analyses, predefined asthma event rates in four 12-week, randomized studies consistently showed numerical or significant differences favoring BUD/FM pMDI over BUD across White, Black, and Hispanic patients, regardless of disease severity. Notably, the results of this analysis showing similar predefined asthma event rates among patients of differing racial backgrounds is consistent with the primary analyses showing the efficacy of BUD/FM pMDI in Blacks\[[@CR7]\] and Hispanics,\[[@CR8]\] as well as a study demonstrating the efficacy of ICS/LABA in Blacks.\[[@CR9]\] Additional discussion of findings and limitations of the individual studies have been previously discussed.\[[@CR5]--[@CR8]\] Differences between the BUD/FM pMDI and BUD groups were smaller in patients with mild to moderate asthma than in patients with moderate to severe asthma, most likely because patients with milder disease had overall lower asthma event rates. These data further support the efficacy of BUD/FM pMDI in achieving asthma control in patients with moderate to severe asthma, regardless of race.

An erratum to this article is available at <http://dx.doi.org/10.2165/11632060-000000000-00000>.
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